Report on Global Ursodeoxycholic Acid by DataM Intelligence estimates the market to grow at a CAGR of 10% during forecast period 2023 - 2030. Ursodeoxycholic Acid usage in chronic cholestatic liver disease is on the rise. Demand from patients suffering from liver disease in Asia Pacific is booming. Competitive rivalry intensifies with AS Grindeks, Erregierre SpA, Daewoong Bio Inc and others operating in the market.
Metrics |
Details |
Market CAGR |
10% |
Segments Covered |
By Type, By Application and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
To Get a Free Sample Click here
The global ursodeoxycholic acid market is segmented geographically by region into North America, South America, Europe, Asia-Pacific, and Rest of the World (RoW).
The Asia-Pacific region is the leading geographical segment by market revenue owing to the rise in production and product sales of the end-products in leading countries such as China and Japan.
The number of patients and prevalence of primary biliary cholangitis, the chronic cholestatic liver disease is increasing in China, with the majority of patients treated with ursodeoxycholic acid medical therapy, thus driving demand for the UDCA market in the region.
The market for ursodeoxycholic acid is moderately competitive, with the development of end-products and elimination of end-products still at a nascent stage.
The key players of the market include Abil Chempharma Private Limited, AS Grindeks, Biotavia Labs Pvt Ltd., Mitsubishi Tanabe Pharma Corporation, and ICE. The companies focus on the expansion of product portfolio and business reach through mergers and acquisitions.
For instance, in June 2016, Retrophin, Inc. announced the signing of a definitive agreement to purchase the rights, titles, and ownership of a liquid formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC.
Report Insights
The synthetic UDCA market segment is expected to continue its domination by market share during the forecast period owing to the development and innovation of the synthesis techniques involved in the manufacturing of synthetic UDCA.
Asia-Pacific is the leading geographical segment due to the rise in production and product sales of the end-products in leading countries such as China and Japan.
The companies are focused on the launch of new products to strengthen market position and increase company revenue. For instance in May 2015, AS Grindeks announced the introduction of the final dosage form (capsule) of Ursodeoxycholic acid (UDCA) and started its export to Russia and Georgia.
The scope of the Report
The report covers the factors impacting the market, Porter 5 Forces, Competitive Scenario, Product Benchmarking, and company profiles. Ursodeoxycholic Acid Market is segmented by type into Synthetic USDA and Extraction USDA. By application, the global Ursodeoxycholic Acid market is segmented into pharmacy and health products.
Geographically, the market is segmented into North America, South America, Europe, Asia Pacific and Rest of the World.
Pharmacy Automation Systems Market